Drug Industry Study Finds a 5,100% ROI for Implementing Authorized Generics Strategies

RESEARCH TRIANGLE PARK, NC--(Marketwired - December 04, 2015) - Data published by Cutting Edge Information found that implementing an authorized generics strategy produces a 5,100% return-on-investment (ROI), higher than any other lifecycle management (LCM) strategy examined in the research.

The study, "Pharmaceutical Lifecycle Management: Expand and Extend Portfolio Value with a Well-Integrated LCM Strategy," published by Cutting Edge Information, found that drug companies continue to invest in authorized generics strategies to maintain profits and avoid patent litigation. One of the primary goals for pharmaceutical brand teams that undertake an authorized generics strategy is to slow the pace of market share decline after market exclusivity loss, according to the study.

Cutting Edge Information researched the cost effectiveness of major pharmaceutical companies' authorized generics strategies and highlighted those findings. Although not as popular as other lifecycle management strategies, authorized generics deliver the most substantial ROI among all of the LCM tactics studied. The study found that for every dollar spent implementing an authorized generics strategy, a drug company receives $51 back.

"Authorized generics strategies were rated as highly effective lifecycle management tactics," said Natalie DeMasi, senior research analyst at Cutting Edge Information. "Companies often turn to authorized generics deals to preserve branded drug sales and avoid lengthy court battles when generic companies file a Paragraph IV certification."

The full study examines the cost effectiveness of 14 different LCM strategies at more than 40 pharmaceutical, biotechnology, medical device and other life science companies. The real-world case studies included are supported by more than 500 quantitative data points, showcasing metrics covering the top lifecycle management strategies that pharmaceutical brand managers implement throughout the industry.

"Pharmaceutical Lifecycle Management: Expand and Extend Portfolio Value with a Well-Integrated LCM Strategy," available at http://cuttingedgeinfo.com/research/portfolio-management/lcm-strategy/, includes detailed metrics and case studies for 14 different lifecycle management strategies, such as new formulations, new dosages, combination products and next-generation products. Metrics include average implementation costs, average return-on-investment, timelines for planning and executing each tactic, as well as primary goals for implementing each strategy.

With this report, LCM executives will understand how top life science companies:

  • Build a robust LCM strategy by combining market enhancement and line extension tactics
  • Create a dedicated LCM team and cross-functional committee to develop the most effective lifecycle management plans
  • Implement strong leadership to ensure a successful LCM strategy
  • Generate excitement with cost-effective publications strategies
  • Invest in next-generation drug development to yield large returns

To learn more about Cutting Edge Information and its research report offerings, please visit http://cuttingedgeinfo.com/.

Image Available: http://www.marketwire.com/library/MwGo/2015/12/3/11G074469/Images/Chapter_2_12-13_Page_1-ac7dfd6abde98775b26c26782dc5849b.jpg

Contact Information:

Rachel Shockley
Marketing Team Lead

Primary LCM Goals of Companies Using Authorized Generics